Denosumab induced recurrent, prolonged and life threatening hypocalcaemia.
No Thumbnail Available
Authors
Olaremi, Japhet
Issue Date
2022
Type
Language
Keywords
Alternative Title
Abstract
Introduction: Denosumab, a human monoclonal antibody used in osteoporosis and second line treatment option for hypercalcaemia, can cause profound hypocalcaemia especially in Vitamin-D depleted and cancer patients.
Description
Citation
Chohan, M.T., Olaremi, J., Pye, S. and Anthony, S. (2022) Denosumab induced recurrent, prolonged and life threatening hypocalcaemia. Endocrine Abstracts; 86 : 189.
Publisher
Endocrine Abstracts
License
Journal
Volume
Issue
PubMed ID
ISSN
1479-6848